New Insights into Dialysis Vascular Access: Molecular Targets in Arteriovenous Fistula and Arteriovenous Graft Failure and Their Potential to Improve Vascular Access Outcomes
New Insights into Dialysis Vascular Access: Molecular Targets in Arteriovenous Fistula and Arteriovenous Graft Failure and Their Potential to Improve Vascular Access Outcomes
复制标题
DOI：
10.2215/cjn.02030216
复制
发表时间：
2016-08-01
影响因子：
9.8
通讯作者：
Misra, Sanjay
中科院分区：
文献类型：
--
作者：
Lee, Timmy;Misra, Sanjay
血管通路功能障碍仍然是血液透析患者发病率和死亡率的主要原因。目前对这一临床问题几乎没有有效的治疗方法。对导致动静脉瘘(AVF)和移植物(AVG)功能障碍的病理生物学认识不足，仍然是开发新的有效治疗方法的关键障碍。然而，近年来，我们在了解血管通路功能障碍的机制方面取得了实质性进展。本文介绍了最近的进展和对AVF和AVG功能障碍的病理生物学的新见解，并强调了改善血管通路结果的潜在治疗靶点。
Vascular access dysfunction remains a major cause of morbidity and mortality in hemodialysis patients. At present there are few effective therapies for this clinical problem. The poor understanding of the pathobiology that leads to arteriovenous fistula (AVF) and graft (AVG) dysfunction remains a critical barrier to development of novel and effective therapies. However, in recent years we have made substantial progress in our understanding of the mechanisms of vascular access dysfunction. This article presents recent advances and new insights into the pathobiology of AVF and AVG dysfunction and highlights potential therapeutic targets to improve vascular access outcomes.